 |
5 Diseases |  |
67 Trials |
|
67 Trials |  |
4266 News |  |
| «12...52535455565758596061626364» |
- risperidone / Generic mfg., olanzapine / Generic mfg.
Trial completion: Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia. (clinicaltrials.gov) - Aug 25, 2015
P=N/A, N=45, Completed, Sponsor: Centre for Addiction and Mental Health
Active, not recruiting --> Completed
- || Arvisol (cannabidiol) / Echo Pharma
Preclinical, Trial primary completion date: CBD-IS: Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study (clinicaltrials.gov) - Aug 21, 2015
P1, N=74, Recruiting, Sponsor: Central Institute of Mental Health, Mannheim
Active, not recruiting --> Completed Trial primary completion date: Jun 2015 --> Oct 2015
- Trial termination, Trial primary completion date: Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression (clinicaltrials.gov) - Aug 21, 2015
P4, N=104, Terminated, Sponsor: Hospital Universitari de Bellvitge
Trial primary completion date: Jun 2015 --> Oct 2015 Recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Jul 2014; Difficulties in recruiting
- |||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Enrollment open: DREaM: A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (clinicaltrials.gov) - Jul 16, 2015
P4, N=275, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Jul 2014; Difficulties in recruiting Not yet recruiting --> Recruiting
- || aripiprazole / Generic mfg.
Trial primary completion date: Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI (clinicaltrials.gov) - Jul 15, 2015
P=N/A, N=90, Recruiting, Sponsor: University of British Columbia
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2015 --> Sep 2015
- |||||| Caplyta (lumateperone) - Intra / Cellular Therapies
Enrollment open: A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment (clinicaltrials.gov) - Jul 11, 2015
P3, N=580, Recruiting, Sponsor: Intra-Cellular Therapies, Inc.
Trial primary completion date: Apr 2015 --> Sep 2015 Not yet recruiting --> Recruiting
- |||| Enrollment open: A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry (clinicaltrials.gov) - Jul 4, 2015
P2, N=155, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | risperidone / Generic mfg., paliperidone extended release / Generic mfg.
Enrollment closed, Enrollment change: A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia (clinicaltrials.gov) - Jun 16, 2015
P4, N=17, Active, not recruiting, Sponsor: Johnson & Johnson Taiwan Ltd
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=50 --> 17
- aripiprazole / Generic mfg., risperidone / Generic mfg.
Trial primary completion date: Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis (clinicaltrials.gov) - Jun 11, 2015
P4, N=242, Active, not recruiting, Sponsor: North Shore Long Island Jewish Health System
Recruiting --> Active, not recruiting | N=50 --> 17 Trial primary completion date: Feb 2014 --> Dec 2014
- Enrollment change, Trial withdrawal: Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=0, Withdrawn, Sponsor: University of Alabama at Birmingham
Trial primary completion date: Feb 2014 --> Dec 2014 N=19 --> 0 | Completed --> Withdrawn
- |||||||||| Caplyta (lumateperone) - Intra / Cellular Therapies
New P3 trial: A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment (clinicaltrials.gov) - Jun 11, 2015
P3, N=580, Not yet recruiting, Sponsor: Intra-Cellular Therapies, Inc.
- risperidone / Generic mfg., olanzapine / Generic mfg.
Enrollment change: Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients (clinicaltrials.gov) - Jun 10, 2015
P4, N=107, Completed, Sponsor: University of California, Los Angeles
N=19 --> 0 | Completed --> Withdrawn N=160 --> 107
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical: DREaM: A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (clinicaltrials.gov) - Jun 9, 2015
P4, N=275, Not yet recruiting, Sponsor: Janssen Scientific Affairs, LLC
N=160 --> 107 Phase classification: P3 --> P4
- |||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Enrollment open, Adherence: Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia (clinicaltrials.gov) - Jun 6, 2015
P4, N=200, Recruiting, Sponsor: Matt Byerly
Phase classification: P3 --> P4 Not yet recruiting --> Recruiting
- ||||| New P2 trial: A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry (clinicaltrials.gov) - Jun 4, 2015
P2, N=155, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- risperidone / Generic mfg.
New P3 trial: Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder (clinicaltrials.gov) - May 28, 2015
P3, N=46, Completed, Sponsor: Nationwide Children's Hospital
- |||||||||| risperidone / Generic mfg., iloperidone / Generic mfg.
New P3 trial: Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia (clinicaltrials.gov) - May 27, 2015
P3, N=288, Recruiting, Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical: DREaM: A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (clinicaltrials.gov) - May 1, 2015
P3, N=275, Not yet recruiting, Sponsor: Janssen Scientific Affairs, LLC
- || risperidone / Generic mfg.
Trial primary completion date: Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia (clinicaltrials.gov) - Apr 29, 2015
P2, N=282, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2009 --> Oct 2005
- |||| risperidone / Generic mfg.
Trial completion: Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia (clinicaltrials.gov) - Apr 27, 2015
P2, N=282, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Jan 2009 --> Oct 2005 Recruiting --> Completed
- New trial: Neuroendocrine and Metabolite Substrates in Schizophrenia (clinicaltrials.gov) - Apr 22, 2015
P=N/A, N=200, Recruiting, Sponsor: Chang Gung Memorial Hospital
- ||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Trial completion: A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia (clinicaltrials.gov) - Apr 20, 2015
P2/3, N=125, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting --> Completed Recruiting --> Completed
- risperidone / Generic mfg., desipramine / Generic mfg.
Trial completion, Enrollment change: RADIAUS: Risperidone and Desipramine in Alcohol Use and Schizophrenia (clinicaltrials.gov) - Apr 20, 2015
P2, N=12, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
Recruiting --> Completed Active, not recruiting --> Completed | N=40 --> 12
- Clinical data, Trial primary completion date: Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis (clinicaltrials.gov) - Apr 19, 2015
P=N/A, N=264, Recruiting, Sponsor: North Shore Long Island Jewish Health System
Active, not recruiting --> Completed | N=40 --> 12 Trial primary completion date: Mar 2015 --> Mar 2019
- |||||||||| New P3 trial, Adverse events: Pharmacovigilance in Gerontopsychiatric Patients (clinicaltrials.gov) - Mar 2, 2015
P3, N=2000, Recruiting, Sponsor: Hannover Medical School
- risperidone / Generic mfg., methamphetamine / Generic mfg.
Trial completion, Enrollment change: A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis (clinicaltrials.gov) - Feb 5, 2015
P4, N=120, Completed, Sponsor: Wei Hao
Trial primary completion date: Mar 2015 --> Mar 2019 Recruiting --> Completed | N=240 --> 120
- Enrollment change, Trial primary completion date: Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=14, Recruiting, Sponsor: Centre for Addiction and Mental Health
Recruiting --> Completed | N=240 --> 120 N=10 --> 14 | Trial primary completion date: Dec 2015 --> Dec 2017
- risperidone / Generic mfg., olanzapine / Generic mfg.
Enrollment closed, Trial primary completion date: Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia. (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: Centre for Addiction and Mental Health
N=10 --> 14 | Trial primary completion date: Dec 2015 --> Dec 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Oct 2015
- || Trial completion: A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder (clinicaltrials.gov) - Feb 3, 2015
P3, N=39, Completed, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Oct 2015 Active, not recruiting --> Completed
- | Trial primary completion date: A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder (clinicaltrials.gov) - Feb 2, 2015
P3, N=39, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Active, not recruiting --> Completed Trial primary completion date: Sep 2015 --> Oct 2014
- || Arvisol (cannabidiol) / Echo Pharma
Preclinical, Trial primary completion date: CBD-IS: Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study (clinicaltrials.gov) - Feb 2, 2015
P1, N=74, Recruiting, Sponsor: Central Institute of Mental Health, Mannheim
Trial primary completion date: Sep 2015 --> Oct 2014 Trial primary completion date: Jun 2014 --> Jun 2015
- ||| Trial completion, Enrollment change: Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants (clinicaltrials.gov) - Jan 26, 2015
P1, N=305, Completed, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Jun 2014 --> Jun 2015 Active, not recruiting --> Completed | N=235 --> 305
- Phase classification: Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study (clinicaltrials.gov) - Jan 15, 2015
P4, N=23, Completed, Sponsor: Georgia Regents University
Active, not recruiting --> Completed | N=235 --> 305 Phase classification: P2 --> P4
- Trial primary completion date: Omega-3 Dietary Supplements in Schizophrenia (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=58, Recruiting, Sponsor: Delbert Robinson
Phase classification: P2 --> P4 Trial primary completion date: Nov 2014 --> Jun 2016
- || aripiprazole / Generic mfg.
Trial primary completion date: Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI (clinicaltrials.gov) - Dec 17, 2014
P=N/A, N=90, Recruiting, Sponsor: University of British Columbia
Trial primary completion date: Nov 2014 --> Jun 2016 Trial primary completion date: Nov 2014 --> Apr 2015
- Clopixol (zuclopenthixol) / Lundbeck, Serlect (sertindole) / Lundbeck, Abbott
Trial primary completion date: Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis (clinicaltrials.gov) - Dec 6, 2014
P3, N=104, Recruiting, Sponsor: Fundación Pública Andaluza Progreso y Salud
Trial primary completion date: Nov 2014 --> Apr 2015 Trial primary completion date: Nov 2013 --> Nov 2015
- | Clopixol (zuclopenthixol) / Lundbeck, Serlect (sertindole) / Lundbeck, Abbott
New P4 trial: Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (clinicaltrials.gov) - Dec 5, 2014
P4, N=25, Recruiting, Sponsor: Technische Universität München
- |||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Enrollment open: Study of the Impact of Aripiprazole (Abilify (clinicaltrials.gov) - Dec 5, 2014
P4, N=80, Recruiting, Sponsor: Deborah Yurgelun-Todd
Trial primary completion date: Nov 2013 --> Nov 2015 Not yet recruiting --> Recruiting
- risperidone / Generic mfg.
Trial completion, Enrollment change: POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia (clinicaltrials.gov) - Nov 19, 2014
P2, N=7, Completed, Sponsor: PharmaNeuroBoost N.V.
Not yet recruiting --> Recruiting Recruiting --> Completed | N=60 --> 7
- ||||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
New P4 trial, Adherence: Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia (clinicaltrials.gov) - Nov 4, 2014
P4, N=200, Not yet recruiting, Sponsor: Matt Byerly
- || asenapine / Generic mfg.
Trial primary completion date: An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308) (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=3000, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed | N=60 --> 7 Trial primary completion date: Jan 2015 --> Dec 2017
- Trial primary completion date: Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression (clinicaltrials.gov) - Oct 22, 2014
P4, N=104, Recruiting, Sponsor: Hospital Universitari de Bellvitge
Trial primary completion date: Jan 2015 --> Dec 2017 Trial primary completion date: Jul 2011 --> Oct 2014
- || Enrollment closed: Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants (clinicaltrials.gov) - Oct 22, 2014
P1, N=235, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Jul 2011 --> Oct 2014 Recruiting --> Active, not recruiting
- | RO5545965 / Roche
Trial completion: A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone (clinicaltrials.gov) - Oct 17, 2014
P1, N=32, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- risperidone / Generic mfg.
Trial primary completion date: Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia (clinicaltrials.gov) - Oct 11, 2014
P2, N=0, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Trial primary completion date: Oct 2005 --> Jan 2009
- BL-1020 / BioLineRx
Enrollment change: Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia (clinicaltrials.gov) - Sep 19, 2014
P2b, N=269, Terminated, Sponsor: BioLineRx, Ltd.
Trial primary completion date: Oct 2005 --> Jan 2009 N=435 --> 269
- ||||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
New P4 trial: Study of the Impact of Aripiprazole (Abilify (clinicaltrials.gov) - Sep 11, 2014
P4, N=80, Not yet recruiting, Sponsor: Deborah Yurgelun-Todd
- | risperidone / Generic mfg., tropisetron / Generic mfg.
Trial completion, Trial primary completion date: Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia (clinicaltrials.gov) - Sep 8, 2014
P3, N=179, Completed, Sponsor: Baylor College of Medicine
N=435 --> 269 Recruiting --> Completed | Trial primary completion date: Mar 2010 --> Feb 2011
- ||| risperidone / Generic mfg.
Enrollment change: CSP #504: Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder (clinicaltrials.gov) - Aug 22, 2014
P2, N=296, Completed, Sponsor: Department of Veterans Affairs
Recruiting --> Completed | Trial primary completion date: Mar 2010 --> Feb 2011 N=400 --> 296
- || risperidone / Generic mfg.
New P3 trial: Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of Schizoaffective (clinicaltrials.gov) - Aug 21, 2014
P3, N=540, Recruiting, Sponsor: Xijing Hospital